Fundraising FoxPolaris Partners — 2022 Investments
13 investments dated 2022 · listed companies and verified rows first · show all
Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
BiotechCambridge, US
Richard Young(Director (Class II))Josh Mandel-Brehm(Chief Executive Officer and Director (Class III))in
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)in
Board seatAmir Nashat· per SEC Form D · filed Jun 2022
Co-investors5AM VenturesAndreessen HorowitzLongwood Fund
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
Jay Caplan(Founder)inHarith Rajagopalan(Co-Founder and CEO)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in
BoardAllan Will(Director)inNimesh Shah(Director)in
Board seatAmy Schulman· per SEC Form D · $20.1M raise · filed Jan 2022
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPGeneral CatalystMithril Capital ManagementDomain Associates+1 more
.png)
US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.
AgTechResearch Triangle Park, US
Scott Uknes(Manager)inEric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)
BoardThomas Dietz(Manager)Kristina Burow(Manager)in
Board seatAmir Nashat· per SEC Form D · $117.2M raise · filed Feb 2022
Co-investorsAliment CapitalBlue Horizon CorporationPontifax AgTechARCH Venture PartnersBill & Melinda Gates FoundationLeaps by Bayer+1 more
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)
Board seatAmir Nashat· per SEC Form D
Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation Endeavors+6 more
Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.
BiotechSeattle, US
Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)
BoardPaulina Hill(Director)inSteven Gillis(Executive Officer, Director, Promoter)in
Board seatTerrance McGuire· per SEC Form D · $102.8M raise · filed Nov 2022
Co-investorsARCH Venture PartnersOUP (Osage University Partners)
Podimetrics offers a remote monitoring and care program for people with complex diabetes, centered on the SmartMat device that collects foot-health data to enable early intervention and prevent complications such as amputations.
Digital HealthHealthtechMedical DevicesSomerville, US
David Linders(Executive Officer, Director)inJonathan Bloom(Executive Officer, Director)
BoardAaron Sandoski(Director)in
Board seatAlexandra Cantley· per SEC Form D · $60M raise · filed Apr 2022
Co-investorsNorwich VenturesScientific Health DevelopmentSV Health InvestorsRock Health
Satellite Bio develops an off-the-shelf cell therapy that delivers functional liver cells (hepatocytes) into the body, where they engraft to restore liver function.
BiotechHealthtechCambridge, US
Christopher Chen(Director, Promoter)inThomas Lowery(Executive Officer)
BoardEllie McGuire(Director)Ling Wong(Director)Sujata Bhatia(Director)William Young(Director)
Co-investorsAlumni VenturesaMoonCatalio Capital Management, LPLightspeed Venture PartnersHighbury HoldingsS32
TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.
AI & Machine LearningBiotechDeep TechHealthtech
Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)
Co-investorsAvego BioScience CapitalDelos CapitalDementia Discovery FundPfizer Venture InvestmentsSV Health InvestorsAgent Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amagma, Inc.Be Me HealthCardurion Pharmaceuticals, Inc.Knowledge FactorTessa Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.